Evidence map›Paper›PMID 40778374›Full record

ArticleMolecular therapy. Oncology2025

Unveiling histotype-specific biomarkers in ovarian carcinoma using proteomics.

Lucas Werner, Ella Ittner, Hugo Swenson, Elisabeth Werner Rönnerman, Claudia Mateoiu, Anikó Kovács, Pernilla Dahm-Kähler, Per Karlsson, Annika Thorsell, Elham Rekabdar and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lucas WernerDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Ella IttnerDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Hugo SwensonDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Elisabeth Werner RönnermanDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Claudia MateoiuRegion Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Pathology, 41345 Gothenburg, Sweden.
Anikó KovácsRegion Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Pathology, 41345 Gothenburg, Sweden.
Pernilla Dahm-KählerDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 41685 Gothenburg, Sweden.
Per KarlssonDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Annika ThorsellProteomics Core Facility at Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
Elham RekabdarProteomics Core Facility at Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
Parisa EsmaeiliDepartment of Immunotechnology, Lund University, 22100 Lund, Sweden.
Fredrik LevanderDepartment of Immunotechnology, Lund University, 22100 Lund, Sweden.
Eva Forssell-AronssonSahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Axel Stenmark TullbergDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Ghassan SaedDepartment of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Toshima Z ParrisDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.
Khalil HelouDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, yet clinical tools for diagnosis, prognosis, and treatment remain limited, and molecular profiling of histotypes is lacking. Here, we leverage proteomic data to further stratify four main EOC histotypes, borderline (BL) and benign (B) tumors, and identify candidate prognostic and diagnostic biomarkers. Using proteomic data from 300 patient samples, we identified differentially abundant proteins (DAPs) such as SNCG, S100A1, VWA2, AGR2, CTH, and SPINK1 and biomarker panels to stratify the tissues. Enrichment of biological processes profiled histotypes and involvement of DAPs. Survival analysis identified candidate biomarkers predicting overall- and disease-specific survival with histotype-specificity. Of these, GLYR1, RPL12, GDPGP1, and POLR2M were associated with favorable outcomes, while SDF4, PPP3CC, EIF2AK2, and STX6 were linked to unfavorable outcomes. Collectively, these findings provide histotype-specific attributes for known and EOC biomarkers that may serve as clinical tools for EOC diagnosis and treatment decisions.

Indexed as

benignbiomarker panelsborderlinedifferential abundance analysisepithelial ovarian cancerhistotypesMT: Regular Issuepathway enrichmentprognostic biomarkerssurvival

Identifiers

PMID40778374
PMCPMC12328698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.